96 related articles for article (PubMed ID: 7920436)
1. Transport mechanism of anthracycline derivatives in rat polymorphonuclear leukocytes: uptake and efflux of pirarubicin.
Nagasawa K; Nomiyama M; Ohnishi N; Yokoyama T; Iwakawa S; Okumura K
Biol Pharm Bull; 1994 May; 17(5):696-700. PubMed ID: 7920436
[TBL] [Abstract][Full Text] [Related]
2. Transport mechanism of anthracycline derivatives in rat polymorphonuclear leukocytes: uptake of pirarubicin, daunorubicin and doxorubicin.
Nagasawa K; Nomiyama M; Ohnishi N; Yokoyama T; Iwakawa S; Okumura K
Biol Pharm Bull; 1994 Sep; 17(9):1305-8. PubMed ID: 7841960
[TBL] [Abstract][Full Text] [Related]
3. Transport mechanism of anthracycline derivatives in rat polymorphonuclear leukocytes: effect of sodium fluoride on pirarubicin uptake.
Nagasawa K; Tsumura A; Kitazawa F; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1995 Feb; 18(2):368-71. PubMed ID: 7742815
[TBL] [Abstract][Full Text] [Related]
4. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells.
Nagasawa K; Natazuka T; Chihara K; Kitazawa F; Tsumura A; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Cancer Chemother Pharmacol; 1996; 37(4):297-304. PubMed ID: 8548874
[TBL] [Abstract][Full Text] [Related]
5. Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin.
Sugiyama T; Sadzuka Y; Nagasawa K; Ohnishi N; Yokoyama T; Sonobe T
Jpn J Cancer Res; 1999 Jul; 90(7):775-80. PubMed ID: 10470291
[TBL] [Abstract][Full Text] [Related]
6. Transport mechanism of pirarubicin in human mononuclear cells.
Nagasawa K; Tsumura A; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Sep; 19(9):1203-9. PubMed ID: 8889041
[TBL] [Abstract][Full Text] [Related]
7. Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells.
Nagasawa K; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Jul; 19(7):971-6. PubMed ID: 8839972
[TBL] [Abstract][Full Text] [Related]
8. Distribution of pirarubicin in human blood.
Nagasawa K; Kitada N; Tsuji C; Ogawa M; Yokoyama T; Ohnishi N; Iwakawa S; Okumura K
Chem Pharm Bull (Tokyo); 1992 Oct; 40(10):2866-9. PubMed ID: 1464120
[TBL] [Abstract][Full Text] [Related]
9. Thermal enhancement of pirarubicin (THP-adriamycin) by mild hyperthermia in vitro.
Takahashi T; Mitsuhashi N; Sakurai H; Murata O; Kitamoto Y; Matsumoto H; Higuchi K; Niibe H
Int J Hyperthermia; 1997; 13(3):317-24. PubMed ID: 9222814
[TBL] [Abstract][Full Text] [Related]
10. Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin.
Vazifeh D; Abdelghaffar H; Labro MT
Antimicrob Agents Chemother; 1997 Oct; 41(10):2099-107. PubMed ID: 9333032
[TBL] [Abstract][Full Text] [Related]
11. Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs.
Nagasawa K; Ohnishi N; Yokoyama T
Jpn J Cancer Res; 1997 Aug; 88(8):750-9. PubMed ID: 9330607
[TBL] [Abstract][Full Text] [Related]
12. Uptake of glycyrrhizin by isolated rat hepatocytes.
Ishida S; Sakiya Y; Ichikawa T; Taira Z
Biol Pharm Bull; 1993 Mar; 16(3):293-7. PubMed ID: 8364475
[TBL] [Abstract][Full Text] [Related]
13. [Conditions for optimal production of active oxygen forms by rat polymorphonuclear leukocytes].
Potselueva MM; Chukhlova EA; Medvedev BI; Evtodienko IuV
Biofizika; 1995; 40(6):1259-64. PubMed ID: 8590719
[TBL] [Abstract][Full Text] [Related]
14. Uptake of the anthracycline pirarubicin into mouse M5076 ovarian sarcoma cells via a sodium-dependent nucleoside transport system.
Nagai K; Nagasawa K; Fujimoto S
Cancer Chemother Pharmacol; 2005 Mar; 55(3):222-30. PubMed ID: 15526202
[TBL] [Abstract][Full Text] [Related]
15. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin.
Nagasawa K; Natazuka T; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Jan; 19(1):100-5. PubMed ID: 8820920
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of pirarubicin activity in multidrug resistant cells by rifampicin.
Furusawa S; Nakano S; Wu J; Sasaki K; Takayanagi M; Takayanagi Y
Biol Pharm Bull; 1997 Dec; 20(12):1303-6. PubMed ID: 9448109
[TBL] [Abstract][Full Text] [Related]
18. Effect of sodium chloride on pirarubicin induced cell killing in P388 mouse leukemia cells.
Furusawa S; Fujimura T; Hayasaka S; Kawauchi H; Sasaki K; Takayanagi Y
Res Commun Chem Pathol Pharmacol; 1991 Jul; 73(1):75-86. PubMed ID: 1882129
[TBL] [Abstract][Full Text] [Related]
19. Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells.
Nagai K; Nagasawa K; Sadzuka Y; Tsujimoto M; Takara K; Ohnishi N; Yokoyama T; Fujimoto S
Cancer Chemother Pharmacol; 2002 Mar; 49(3):244-50. PubMed ID: 11935217
[TBL] [Abstract][Full Text] [Related]
20. Comparison of cardiac actions of doxorubicin, pirarubicin and aclarubicin in isolated guinea-pig heart.
Temma K; Akera T; Chugun A; Kondo H; Hagane K; Hirano S
Eur J Pharmacol; 1993 Apr; 234(2-3):173-81. PubMed ID: 8482324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]